NO20064794L - Anvendelse av anti-alfa5beta1-antistoffer for inhibering av kreftcelleproliferasjon - Google Patents

Anvendelse av anti-alfa5beta1-antistoffer for inhibering av kreftcelleproliferasjon

Info

Publication number
NO20064794L
NO20064794L NO20064794A NO20064794A NO20064794L NO 20064794 L NO20064794 L NO 20064794L NO 20064794 A NO20064794 A NO 20064794A NO 20064794 A NO20064794 A NO 20064794A NO 20064794 L NO20064794 L NO 20064794L
Authority
NO
Norway
Prior art keywords
cancer
antibodies
methods
cancer cell
cell proliferation
Prior art date
Application number
NO20064794A
Other languages
English (en)
Norwegian (no)
Inventor
Vanitha Ramakrishnan
Vinay Bhaskar
Sun Ho
Richard Murray
Debbie Law
Original Assignee
Pdl Biopharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pdl Biopharma Inc filed Critical Pdl Biopharma Inc
Publication of NO20064794L publication Critical patent/NO20064794L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2842—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta1-subunit-containing molecules, e.g. CD29, CD49
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
NO20064794A 2004-03-24 2006-10-23 Anvendelse av anti-alfa5beta1-antistoffer for inhibering av kreftcelleproliferasjon NO20064794L (no)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US55642204P 2004-03-24 2004-03-24
US55642104P 2004-03-24 2004-03-24
US62504904P 2004-11-03 2004-11-03
US65109805P 2005-02-07 2005-02-07
US65751405P 2005-02-28 2005-02-28
PCT/US2005/009939 WO2005092073A2 (en) 2004-03-24 2005-03-24 Use of anti-alpha5beta1 antibodies to inhibit cancer cell proliferation

Publications (1)

Publication Number Publication Date
NO20064794L true NO20064794L (no) 2006-10-23

Family

ID=35056776

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20064794A NO20064794L (no) 2004-03-24 2006-10-23 Anvendelse av anti-alfa5beta1-antistoffer for inhibering av kreftcelleproliferasjon

Country Status (15)

Country Link
US (2) US7662384B2 (ko)
EP (1) EP1755659B1 (ko)
JP (1) JP4857259B2 (ko)
KR (1) KR20070009637A (ko)
AT (1) ATE531388T1 (ko)
AU (1) AU2005226736B2 (ko)
BR (1) BRPI0509177A (ko)
CA (1) CA2560508A1 (ko)
DK (1) DK1755659T3 (ko)
ES (1) ES2376556T3 (ko)
HK (1) HK1101348A1 (ko)
IL (1) IL178042A (ko)
NO (1) NO20064794L (ko)
NZ (1) NZ549893A (ko)
WO (1) WO2005092073A2 (ko)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2007225044C1 (en) 2006-03-15 2018-03-29 Alexion Pharmaceuticals, Inc. Treatment of paroxysmal nocturnal hemoglobinuria patients by an inhibitor of complement
BRPI0709338A2 (pt) * 2006-03-21 2011-07-12 Genentech Inc anticorpo, molécula de ácido nucleico isolada, célula, composições, método de detecção da proteìna alfa5beta1, uso de anticorpo, métodos de tratamento, kit, uso de uma composição, uso de uma antagonista de alfa5beta e uso de uma antagonista de vegf
WO2007114851A1 (en) * 2006-04-04 2007-10-11 The Board Of Trustees Of The University Of Illinois Methods and compositions to induce cell death of invasive tumors
KR20090027218A (ko) * 2006-05-24 2009-03-16 바이엘 쉐링 파마 악티엔게젤샤프트 면역원성이 감소된, 고친화도 인간 및 인간화된 항-α5β1 인테그린 작용 블로킹 항체
WO2008061377A1 (en) * 2006-11-22 2008-05-29 Centre Hospitalier De L'universite De Montreal Novel receptor for cd40l and uses thereof
EP2193148A2 (en) * 2007-07-27 2010-06-09 Facet Biotech Corporation Pharmaceutical combinations comprising a tyrosine kinase inhibitor and an antibody against integrin alpha 1 beta 5 (cd49e)
MX2010003325A (es) * 2007-09-26 2010-04-09 Genentech Inc Anticuepos novedosos.
BRPI0906387A2 (pt) * 2008-02-05 2015-07-07 Bristol Myers Squibb Co Anticorpos alfa 5 - beta 1 e seus usos
AU2009331528A1 (en) 2008-12-23 2011-08-11 Astrazeneca Ab Targeted binding agents directed to alpha5beta1 and uses thereof
PE20120770A1 (es) * 2009-03-25 2012-07-10 Genentech Inc ANTICUERPOS ANTI alfa5ß1 CON ACTIVIDAD SOBRE GLIOBLASTOMAS
US20110319335A1 (en) 2010-06-23 2011-12-29 Xiaodong Feng Combined administration of integrin receptor antagonists for anti-angiogenic therapy
EP4088736A1 (en) 2011-10-25 2022-11-16 Prothena Biosciences Limited Humanized anti-amyloid antibody formulations and methods
US8946159B2 (en) 2011-12-22 2015-02-03 California Northstate College Of Pharmacy, Llc Administration of an antagonist of α5β1 for anti-angiogenesis and cancer treatment
NO2760138T3 (ko) 2012-10-01 2018-08-04
JOP20190260A1 (ar) 2017-05-02 2019-10-31 Merck Sharp & Dohme صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها
RU2019138507A (ru) 2017-05-02 2021-06-02 Мерк Шарп И Доум Корп. Составы антител против lag3 и совместные составы антител против lag3 и антител против pd-1

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4704366A (en) * 1984-06-22 1987-11-03 Bio-Rad Laboratories, Inc. Process for binding IgG to protein A
JPS61134325A (ja) * 1984-12-04 1986-06-21 Teijin Ltd ハイブリツド抗体遺伝子の発現方法
US5618920A (en) * 1985-11-01 1997-04-08 Xoma Corporation Modular assembly of antibody genes, antibodies prepared thereby and use
US4946778A (en) * 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US4801687A (en) * 1986-10-27 1989-01-31 Bioprobe International, Inc. Monoclonal antibody purification process using protein A
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5558864A (en) * 1991-03-06 1996-09-24 Merck Patent Gesellschaft Mit Beschrankter Haftung Humanized and chimeric anti-epidermal growth factor receptor monoclonal antibodies
AU669124B2 (en) * 1991-09-18 1996-05-30 Kyowa Hakko Kirin Co., Ltd. Process for producing humanized chimera antibody
GB9125979D0 (en) * 1991-12-06 1992-02-05 Wellcome Found Antibody
US5863537A (en) * 1992-02-19 1999-01-26 Schering Corporation Humanized monoclonal antibodies against human interleukin-4
US5639641A (en) * 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
EP0669988B2 (en) 1992-10-29 2009-07-08 The Australian National University Angiogenesis inhibitory antibodies
US5536814A (en) * 1993-09-27 1996-07-16 La Jolla Cancer Research Foundation Integrin-binding peptides
US5981478A (en) 1993-11-24 1999-11-09 La Jolla Cancer Research Foundation Integrin-binding peptides
AU1925195A (en) 1994-02-22 1995-09-04 Dana-Farber Cancer Institute Nucleic acid delivery system, method of synthesis and uses thereof
EP0704920B1 (en) * 1994-09-21 2000-04-19 Matsushita Electric Industrial Co., Ltd. Solid-state lithium secondary battery
US5705154A (en) * 1995-03-08 1998-01-06 Schering Corporation Humanized monoclonal antibodies against human interleukin-4
WO1997033887A1 (en) 1996-03-15 1997-09-18 Du Pont Pharmaceuticals Company Spirocycle integrin inhibitors
US5922676A (en) * 1996-09-20 1999-07-13 The Burnham Institute Methods of inhibiting cancer by using superfibronectin
US5846536A (en) 1996-10-04 1998-12-08 The Regents Of The University Of California Restoration of normal phenotype in cancer cells
WO1998032771A1 (fr) 1997-01-29 1998-07-30 Toray Industries, Inc. Proteines chimeres, complexes heterodimeres de ces proteines et substituant de plaquette
US6171586B1 (en) * 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
AU2444899A (en) * 1998-01-22 1999-08-09 Astrazeneca Ab Pharmaceutical formulation comprising an antibody and a citrate buffer
CA2330277A1 (en) 1998-04-27 1999-11-04 Sidney Kimmel Cancer Center Reduced complexity nucleic acid targets and methods of using same
US6852318B1 (en) 1998-05-08 2005-02-08 The Regents Of The University Of California Methods for detecting and inhibiting angiogenesis
WO1999058139A2 (en) * 1998-05-08 1999-11-18 The Regents Of The University Of California Methods for detecting and inhibiting angiogenesis
EP1204764A2 (en) 1999-08-11 2002-05-15 EOS Biotechnology, Inc. Methods of screening for angiogenesis modulators
EP1252162B1 (en) 2000-01-20 2012-07-25 Merck Sharp & Dohme Corp. Alpha v integrin receptor antagonists
JP2003520271A (ja) 2000-01-24 2003-07-02 メルク エンド カムパニー インコーポレーテッド αｖインテグリン受容体拮抗薬
US7740841B1 (en) * 2000-01-28 2010-06-22 Sunnybrook Health Science Center Therapeutic method for reducing angiogenesis
US20040259152A1 (en) * 2000-02-22 2004-12-23 Richard Murray Novel methods of diagnosing and screening for modulators of tissue remodeling and treating related diseases
JP2004531249A (ja) 2001-02-14 2004-10-14 プロテイン デザイン ラブス インコーポレイティド 血管新生の診断方法、組成物、及び血管新生モジュレータのスクリーニング方法
CN100369930C (zh) * 2002-11-26 2008-02-20 Pdl生物制药股份有限公司 调节血管生成的α5β1整合素的嵌合的和人源化的抗体
US7276589B2 (en) * 2002-11-26 2007-10-02 Pdl Biopharma, Inc. Chimeric and humanized antibodies to α5β1 integrin that modulate angiogenesis
CA2520121A1 (en) * 2003-04-03 2004-10-21 Protein Design Labs, Inc. Inhibitors of integrin alpha5beta1 and their use for the control of tissue granulation
KR101441358B1 (ko) * 2003-05-14 2014-09-24 이뮤노젠 아이엔씨 약물 콘쥬게이트 조성물

Also Published As

Publication number Publication date
DK1755659T3 (da) 2012-02-27
IL178042A (en) 2011-05-31
ATE531388T1 (de) 2011-11-15
AU2005226736A1 (en) 2005-10-06
JP2007530584A (ja) 2007-11-01
WO2005092073A3 (en) 2006-08-10
BRPI0509177A (pt) 2007-09-18
EP1755659A4 (en) 2008-08-20
ES2376556T3 (es) 2012-03-14
US20100291111A1 (en) 2010-11-18
WO2005092073A2 (en) 2005-10-06
KR20070009637A (ko) 2007-01-18
HK1101348A1 (en) 2007-10-18
US20050260210A1 (en) 2005-11-24
JP4857259B2 (ja) 2012-01-18
AU2005226736B2 (en) 2009-11-26
EP1755659A2 (en) 2007-02-28
NZ549893A (en) 2010-05-28
US7662384B2 (en) 2010-02-16
CA2560508A1 (en) 2005-10-06
EP1755659B1 (en) 2011-11-02
IL178042A0 (en) 2006-12-31

Similar Documents

Publication Publication Date Title
NO20064794L (no) Anvendelse av anti-alfa5beta1-antistoffer for inhibering av kreftcelleproliferasjon
ATE546158T1 (de) Therapeutisches krebsmittel mit polymergebundenem antikörper
CY1119956T1 (el) Μονοκλωνικα anti-gt468 αντισωματα για θεραπεια καρκiνου
EA200801853A1 (ru) Пептиды, эффективные в лечении опухолей и других заболеваний, требующих удаления или разрушения клеток
EA200601433A1 (ru) Способы и композиции для лечения опухолей и метастазирования
DE602005027617D1 (de) Radiotherapiebehandlungsüberwachung unter einsatz von ultraschall
ATE512146T1 (de) Phenylharnstoffderivate als hemmstoffe von tyrosinkinasen zur behandlung von tumorerkrankungen
MX2009006779A (es) Antagonistas especificos para terapia con adyuvantes y neo-adyuvantes y el tratamiento de tumores en etapa temprana.
NO20070951L (no) Inhibitorer av angiopoientinlignende-4-protein, kombinasjoner og deres anvendelse.
DE60027768D1 (de) Behandlung von metastatischer krankheit
WO2004000094A3 (en) Predictive markers in cancer therapy
CY1114006T1 (el) Τοπικα σκευασματα συνενζυμου q10 και μεθοδοι χρησης
ATE294591T1 (de) Verwendung von trifunktionellen bispezifischen und trispezifischen antikörpern zur behandlung von malignem aszites
DE602005023488D1 (de) Tumorassoziierte antigenprofile in der krebsdiagnostik und immuntherapie
NO20071585L (no) Ny anvendelse av peptidforbindelser for behandling av benkreftsmerte, kjemoterapi- og nucleosidfremkalt smerte
TW200626900A (en) Wnt proteins and detection and treatment of cancer
ATE526037T1 (de) Verfahren zum abtöten von tumorzellen mittels targeting von auf apoptotischen tumorzellen exponierten internen antigenen
HK1116186A1 (en) Azaxanthones and use thereof for treating tumors
MX2019015194A (es) Composiciones y métodos para terapia de cáncer con virus de dengue y células dendríticas.
DE60038624D1 (de) Methoden zur behandlung von festen tumoren und metastasen mit gentherapie
WO2013104050A3 (en) Methods of treating triple negative breast cancer and basal-like breast cancer using inhibitors against kidney associated 1 (kaag1) inhibitor
UA88294C2 (ru) ПРИМЕНЕНИЕ АНТИ-α5β1 АНТИТЕЛ ДЛЯ УГНЕТЕНИЯ ПРОЛИФЕРАЦИИ РАКОВЫХ КЛЕТОК
ATE493431T1 (de) An der oberfläche befindliche campylobacter jejuni-polypeptide
ATE431742T1 (de) Modifizierte zytokine für krebs therapie
MX2021012011A (es) Agentes anti-ccr5 y metodos de tratamiento que bloquean la metastasis del cancer o intensifican la muerte celular inducida por quimioterapia da?ina al adn.

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application